3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
7
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Non-metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
durvalumab
3
abemaciclib
2
Pemetrexed
2
Fulvestrant
2
Cisplatin
2
Carboplatin
2
ribociclib
1
repotrectinib
1
pembrolizumab
1
palbociclib
1
exemestane
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
RAD1901
1
Nivolumab
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Drug Therapy
1
Docetaxel
1
Bevacizumab
1
Anastrozole
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
darolutamide
×
30 days
×
Clear all
No trials found.